Over 11,000 bottles of a popular blood pressure medication have been recalled after failing quality tests, the U.S. Food and Drug Administration (FDA) announced. The voluntary recall, initiated on June 5, 2026, affects 11,460 bottles of Chlorthalidone Tablets manufactured by India-based Inventia Healthcare Limited and distributed by New Jersey-based Rising Pharma Holdings.
Recall Details and Reason
The recalled tablets are a diuretic, commonly known as a “water pill,” used to treat hypertension and reduce excess fluid buildup caused by heart, kidney, or liver disease. According to the FDA, the recall was prompted by “failed dissolution specifications,” meaning the tablets did not break down correctly in the body. This failure can render the drug less effective than intended, potentially compromising patient treatment.
The affected bottles contain either 1,000 or 100 tablets, and all have an expiration date of April 2027. Patients and healthcare providers are advised to check their supplies and discontinue use of any recalled bottles.
Recent UK Recall of Similar Drug
This recall follows a separate incident in the United Kingdom last month. On May 28, 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that Crescent Pharma Limited was recalling one batch of Ramipril 2.5mg capsules as a precautionary measure. The recall was due to a packaging error that may have resulted in some cartons containing blister strips of a higher dose—specifically Ramipril 10mg—instead of the intended 2.5mg dose.
Regulatory Oversight
Regulatory bodies in both the U.S. and the U.K. emphasize their commitment to ensuring consumer safety. The FDA and MHRA work to identify and address potential risks associated with pharmaceutical products, issuing recalls when necessary to prevent harm.
